Research programme: TNF antagonists - Xencor

Drug Profile

Research programme: TNF antagonists - Xencor

Alternative Names: TNF monoclonal antibodies - Xencor; Tumour necrosis factor antagonists - Xencor; XmAb 6755; Xtend-TNF

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Xencor
  • Class Monoclonal antibodies; Proteins; Tumour necrosis factors
  • Mechanism of Action RANK ligand inhibitors; Tumour necrosis factor alpha inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Autoimmune disorders; Bone disorders
  • Discontinued Inflammation

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Bone-disorders in USA (Parenteral)
  • 11 Apr 2014 A biosuperior anti-TNF, Xtend-TNF, monoclonal antibody is still in preclinical trials for Autoimmune disorders in USA (Xencor's pipeline)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top